Microarray technology is a tremendously powerful method for simultaneously monitoring the expression of thousands of species of nucleic acids, usually cellular mRNA, producing a highresolution representation of the genes encoded or expressed in a cell. As such, microarray technology has great potential for impacting research and clinical approaches to treatment. However, this complex technology has been challenging to apply as a result of difficulties discerning biologic variation from technologic issues, therefore slowing the application of the technology to human diagnostics. Nevertheless, significant advances in microarray technology, improvements that avoid potential pitfalls, and a wider spectrum of application are making this technology easier to apply. Indeed, microarray technology has provided valuable insights into mechanisms involving gene regulation and expression in Alzheimer disease, and it remains a powerful tool to identify biomarkers for disease diagnosis. Ultimately, the most robust markers will enable the application of more specific treatments particular to disease stages or subcategories. Currently, no widely applicable molecular test is available to identify those at risk for developing Alzheimer disease or those who have early markers of pathology but show discernible cognitive impairment. The progression of this technology will lead to earlier detection of the disease through enhanced understanding of disease onset and progression.
INTRODUCTION
Alzheimer disease (AD) is an incurable and fatal disease that affects a significant proportion of the elderly population. A higher percentage of the population is now susceptible to developing AD as a result of an increased life expectancy. This fact suggests that AD will continue to burden society, making the disease an increasingly important candidate for advanced study in prevention and treatment. Significant therapeutic advancements have recently been made, including some that show promise in preventing disease onset and progression. The Alzheimer's Association has previously advocated that a breakthrough in preventing AD could happen as soon as 2010 with sufficient funding. This is significant news for the 7.7 million people in the United States who are projected to develop the disease in the next 25 years.
AD is the most prevalent neurodegenerative disease in the world; however, the specific pathogenic factors responsible for initiating the disease process have yet to be identified. Analysis has revealed that multiple processes are involved in the onset and progression of AD. The pathologic hallmarks identified in postmortem brain tissue include accumulations of hyperphosphorylated tau, referred to as neurofibrillary tangles (NFTs), and senile plaques, composed of amyloid-A (AA) peptides. A number of other phenomena have been characterized, but the timing, order, and significance of these events are still disputed. One such phenomenon is synaptic dysfunction attributed to microtubule disruption and deficiencies in transport proteins, which leads to significant cognitive decline (1) . Another is the loss of genes involved in synaptic vesicle trafficking in AD (2) .
Evidence regarding NFTs has shown a high correlation with cognitive state, and neurofibrillary degeneration is necessary for dementia to occur (3, 4) . Studies of tau mutations thought to be responsible for frontotemporal dementia with Parkinsonism linked to chromosome 17 support the notion that neurofibrillary degeneration involving these tau mutations are a primary cause of dementia (5) . Oxidative stress and aberrant cell-cycle reentry are also found to be highly specific for AD and may be factors that initiate the pathologic markers that are used for diagnosis (6Y8). Inflammation, protein folding, and the effects of growth hormones or growth factors on neurons have also been implicated in the disease process (9, 10) .
A great deal of progress has been made in recent years in understanding the characteristics of AA. The BAmyloid Cascade Hypothesis,[ which supports AA peptide generation as the initiator of disease pathogenesis, is based on identified genetic factors leading to early onset AD (11) . Further revisions of the theory (12) have led to studies that have provided support that AA is directly implicated in the disease. Despite these advances, the precise mechanisms behind this disease have remained elusive. In other disease states, significant advances have been made using multiplex technologies to analyze nucleic acids, proteins, and metabolites. This review covers some of the potentials, pitfalls, and results of forays into the nucleic acid space with microarrays, especially in regard to AD research.
The Fine Print of Microarray Technology: A Technologic Evolution of Technologies
To understand microarray technology and the results of observations with these systems, a historical perspective of the evolution of the technology is helpful. The origins of multiplex analysis of mRNA (i.e. gene expression) date back to radiolabeled Northern blots and slot blot hybridizations, which were widely used using nylon membranes as a substrate to bind either the nucleic acid target or probe. These methods were widely used; however, the expression of only a few genes could be explored in each experiment. Later forms of larger multiplex (hundreds of spots) Bmacroarray[ blots on nylon became favored because of their reusability, and they served as precursors for the microarray. The terms Btarget[ and Bprobe[ have been used interchangeably over the last 2 decades; in this article, the author refers to the Btarget[ as the pool of messenger RNA (or labeled cDNA) being interrogated by the Bprobe[V generally a short stretch of nucleic acid. In microarrays, the probe is immobilized to the substrate; the target is the labeled material in solution.
The development of spotted cDNA microarrays on glass substrates heralded the arrival of true multiplex gene analysis (13) . These systems avoided the need to radiolabel the sample. Instead, they used fluorescent dyes, usually cyanine dyes, and used high-resolution quantitative fluorescent imagers to Bread[ the microarray. The probes were generated through the arduous process of polymerase chain reaction (PCR) amplification of regions in cDNA clones, resulting in large libraries of probes (PCR amplicons) in multiwell plates. These probes were then Bshrunk[ onto thousands of spots, each a few tenths of a millimeter in diameter, on the surface of a glass slide by spotting the cDNA onto the surface of glass microscope slides with precision-made metal spotting pins. Although the method was widely adopted by Bcore labs,[ this technique has a number of problems. First, the spotting process is highly sensitive to environmental factors such as dust contamination and humidity; therefore, expensive clean-room facilities were required. Even with these controls, spot morphology was very difficult to control consistently, leading to significant observed variation when comparing replicates on the same array. To counter this variability, a number of normalization strategies evolved, the most common of which is generally termed B2-color normalization,[ which relies on the analysis of the ratio of 2 RNA targets labeled with different fluorophores in the same spot. Second, the surface chemistry of the glass slide was critical, and it was difficult to maintain batch consistency in surface chemistry. This spawned a cottage industry of glass slide manufacturers, each producing different slides with competing chemistries, resulting in more complex surface chemistry and handling. As a result, lab-to-lab variability grew and ultimately no great improvements in batch-to-batch variability were achieved. Unfortunately, in the gold rush to apply microarray technology to biologic problems, much of the technologic knowledge required to make and use the system consistently was lost as new technology propagated. As a result, microarray fabrication experienced differences in manufacturing and quality control (or lack thereof). Furthermore, there were significant differences in the probes' sequences, composition, and length, each of which was based on the amplification strategy and the source of the cDNA (e.g. inclusion/exclusion of certain exons from splice variants, and so on). Inattentiveness to the immobilization chemistry that ensured the probe would remain attached to the glass substrate during the hybridization resulted in even greater variability and more confusion.
The 1990s also saw the advent of in situ synthesis technologies for microarrays, the most well known of which was the Affymetrix Gene Chip (14, 15) . This system relied on photomask technology from the semiconductor industry and light-sensitive chemistries to pattern the synthesis of short DNA oligonucleotides onto the surface of a modified glass substrate. The Affymetrix technology relied on the synthesis of 25'mer probes, which was perceived as the optimal probe length to balance synthesis efficiency and assay performance. This approach was very different from spotted cDNA arrays (which generally used probes of 200Y600 bases in length) and, not surprisingly, it became difficult to get clear correlations between the 2 platforms. The Affymetrix platform used a battery of extremely short, mismatch sensitive oligos to probe a transcript, whereas the spotted cDNA relied on PCR fragments that, in the latter case, tended to produce strong but not entirely specific hybridization signals. Perhaps not surprisingly, although hundreds of laboratories have used these 2 platforms to catalog the expression of genes from normal and diseased tissues, there has been limited integration of the collective expression findings. Indeed, despite many technical reviews of microarray technology that have been produced to assist investigators (16, 17) , the critical issues that affect microarray performance are still not widely understood. Recent studies that have demonstrated problems with microarray concordance between platforms (18) have been reevaluated by the U.S. Food and Drug Administration (FDA) (National Center for Toxicological Research) and shown to be a result of technical issues rather than problems with the technology itself. Analysis showed that intraplatform consistency was low, which was responsible for the low concordance between platforms (19) . This implies that great care must be taken to ensure standardization of samples for a given platform and reemphasizes this core issue with microarray technology: use of these complex systems requires new solutions to reduce the risk of user error.
Newer generations of microarray technologies, which rely on different technologies for production, have evolved more recently. Some technologies use light-based chemistries, similar to that of Affymetrix, but use digital light processors to pattern the synthesis of microarrays (Nimblegen, Madison, WI). Others rely on completely different principles to synthesize DNA such as the ink jet technology-based deposition of DNA-precursor phosphoramidites (Agilent, Palo Alto, CA) and electrochemically synthesized microarrays (CombiMatrix, Mukilteo, WA). Other classes of microarrays rely on secondary manipulation of beads on which DNA has been synthesized (Illumina, San Diego, CA). More evolved forms of spotted microarrays depend on improved deposition techniques and longer oligomers. Table 1 provides information regarding current microarray manufacturers and the details of their systems. Table 2 provides information regarding probe length and the particular attributes of those systems.
Each one of these technologies addresses the core issues of microarray technology differently. The substrates for the arrays vary widely from polymer-coated glass, beads, or even silicon computer chips. However, these fundamental differences in oligo length, density, and immobilization tend to cause platform specific variations in performance that generally lead to imprecise quantitative parity between platforms, although the trends in gene expression (i.e. those genes up-or downregulated) may be preserved. Furthermore, differences in oligo quality or purity can also change the behavior of a microarray platform. A precise definition of stepwise yield is difficult to obtain for most microarray platforms, which is critical for understanding system performances. Certainly particular chemistries such as photodetritylation chemistries are known to be inefficient and are only suitable for the synthesis of short oligomers. All oligonucleotides contain impurities as part of the synthesis, and no platform, spotted or in situ synthesized, is able to provide oligos purified to homogeneity. In fact, this issue is rarely addressed in spotted microarrays because it is prohibitively expensive to buy multiple batches of oligos to test these effects; rather, a single source of oligos is shared within a facility. Here differences in the quality of oligo synthesis can manifest themselves as lab-to-lab differences (if the same oligo pool is not used). Irrespective of the differences between the various platforms, the oligonucleotidebased microarray has become the system of choice because it is possible to design the oligonucleotides with a series of criteria that will ensure they perform in a much more predictable manner than cDNA arrays. Specifically, oligonucleotides can be chosen so they only bind a specific gene or splice variant and nothing else. They can also be designed so that they are thermodynamically matched (i.e. at a specific hybridization temperature, they will all be at or close to their optimum binding state for specific hybridization). Furthermore, the flexibility given by some platforms allows a user to specify precisely which oligos, and therefore which genes, will appear on a given array. This specificity is possible but generally impractical with centralized spotted microarray systems. Despite these system-specific differences, the day-to-day performance of microarray platforms has improved dramatically as the technology has evolved. Now, within one platform, the biologic noise of the sample and differences in user handling are the primary causes of variability in microarray analysis.
Complex sample amplification strategies indicate that reasonably small (nanogram) quantities of material can now be used in microarray analysis and that these tools are no longer confined to the realms of in vitro systems or in vivo models. Microarrays can be applied to the multiplex analysis of almost any population of nucleic acids, and although the clearest picture for gene expression analysis can be obtained with RNA purified from fresh tissue, a variety of other samples can be used for microarray analysis. These include frozen tissue, peripheral blood, and DNA, which can be recovered from serum, urine, and saliva. Sample amplification strategies can be applied to very small amounts of starting material such as those from laser capture microdissection samples and even, in limited circumstances, single 
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Average Tm for a 50% GC probe 55-C 7 3 -C 8 0 -C Specificity: loss of degrees Celsius per 2 mismatches 20-C 1 2 -C 6 -C Effect of a 1,000-fold change on probe Tm 10-C 5.5-C 3.7-C Synthesis fidelity (assuming 99%/cycle) 81% of probes are full-length 70% of probes are full-length 50% of probes are full-length cells. However, the latter has proven to be somewhat difficult as a result of the high level of cell-to-cell variability in single-cell gene expression. Paraffin-embedded formalin fixed tissue can also be used for gene expression studies using appropriate amplification strategies, although the quality of the RNA can be poor. The advantage of these samples is that the study can be done retrospectively rather than prospectively. Indeed, prospective gene expression studies on the hippocampi of patients with AD are clearly impossible; therefore, the approaches for analyzing postmortem, embedded samples have been most important (20) .
A number of additional challenges face the microarray researcher with sample processing. On the positive side, a variety of tools exist for preserving RNA samples effectively (e.g. RNAlater, RNAsecure; Ambion, Austin, TX). Many manufacturers now produce analytical systems well suited to the small sample volumes encountered in microarray analysis such as BNanodrop[ spectrophotometers and simple capillary electrophoresis systems designed to assess the quality of DNA or RNA amplification. Despite the ability to judge the integrity of amplified nucleic acids, none of these methods can give useful information on the composition of the materials isolated or amplified. For example, the most commonly used mRNA amplification technique, based on the method developed by Eberwine and Van Gelder (21), produces significant signal bias to the 3_ end. This indicates that a full-length mRNA transcript hybridized to the microarray is represented predominantly by species derived from sequences at the 3' end of the transcript. This can be problematic and is likely one of the most significant sources of variation in oligonucleotide array platform performance because each provider designs oligonucleotides at different loci with different lengths. This 3' bias issue has often led to data that varies with quantitative reverse transcription PCR (Q-RTPCR) assays, which have been used to Bvalidate[ gene expression data. Whereas Q-RTPCR is a valid technique and certainly reproducible under the right circumstances, it remains a technique that is precise but not necessarily accurate. The method demonstrates exponential amplification and exquisite sensitivity not only to sample, but also error sample contaminate introduced during the pipetting of the reaction. Despite these issues, Q-RTPCR certainly has a significant role to play in the Blow-density[ (1Y500 probe) analysis of gene expression and is commonly used as an adjunct to hybridization data. Meanwhile, the issue of amplification bias is still being understood and characterized. To what degree sample-to-sample ratios can compensate for the amplification bias and to what degree amplification can bias an mRNA sample is still a controversial issue.
One issue of particular interest in AD samples is to what degree the effects of oxidative stress may bias the nucleic acids extracted from AD brains because RNA oxidation is evident in vulnerable neurons in AD (22Y24). Although there is no evidence that oxidized RNA affects the isolation process of RNA from tissue, it could bias the mRNA expression profile. The modification of nucleosides may affect the amplification process during microarray analysis and, if so, the level of mRNA in the microarray does not represent the original level of mRNA. This may be a complicating factor and tend to bias the gene expression data observed to nonneuronal cell types. Although problematic for research studies, this phenomenon should be less marked for surrogate (i.e. distant from the brain) biomarkers.
Most of the issues related to acquiring high-quality images of fluorescently labeled microarrays are better understood. Then again, tools that are available for rigorous calibration of imaging systems are often avoided leading to poor image acquisition and noisy data sets. Given that the majority of microarrays rely on some sort of fluorescent imaging process with subsequent analysis of the image, this source of error is frequently underestimated. The systems that avoid the technical issues associated with fluorescence generally rely on electrical measurements of hybridization (Nanogen, CombiMatrix). Basic imaging issues usually are related to focusing and ensuring the planarity of the microarray to the optics because most laser scanners have a depth of focus of T 20 to 30 Km. Other common issues are dye photobleaching as a result of overillumination, dye quenching as a result of overlabeling of target nucleic acids, and poor choices of dye species relative to the capability of the scanner. An excellent article on the data introduced in microarray data by problems with laser scanning can be found in Shi et al (25) . In addition to physical problems, a number of unusual chemical problems have been causing problems with microarray consistency. Recently, ozone has been identified as a major problem with certain spotted microarrays and those using glass slide-like chemistries, especially Agilent. The sensitivity on a number of these systems is extreme, and the ozone levels common in innercity areas are frequently high enough to cause major variability in microarray performance. Mitigation and measurement requires isolating the work area with carbon filtration to reduce the ozone level, which can be a logistic headache. Interestingly, microarray systems that can be imaged Bwet[ (i.e. when no drying step is used before imaging) do not seem to experience this phenomenon.
Data analysis techniques have been successfully applied to Bgate[ data and prevent very noisy data from entering analyses. The wide variety of tools available for data analysis, the circumstances under which they should be applied and how they should be applied is beyond the scope of this review. Ultimately, the best solution is to minimize as many elements of noise in the data as possible and seek to understand and quantify those sources of noise that cannot be eliminated by technologic improvements (such as biologic variation).
The development of standards for microarray platforms is currently underway through at least 3 initiatives in the United States alone, specifically the Microarray Quality Control Study (MAQC), the National Institute of Standards and Technology (NIST), and Technology External RNA Controls Consortium (ERCC). Ultimately, all of these initiatives and others will provide the necessary information for guidelines that will give the Centers for Disease Control and Prevention and the FDA shared responsibility for monitoring molecular diagnostic testing. Each system currently used has inherent errors and data outcomes that make it difficult to compare results prepared from different setups. Indeed, controlling and predicting errors in each system should allow for integration and appropriate development in the future.
AD remains difficult to diagnose because molecular markers for early-stage disease may overlap with the normal aging process. The ability to monitor multiple cellular pathways simultaneously allows for significant diagnostic capabilities. Still, interpretation is hindered by low statistical power and a relatively high number of false-positives, both of which are significant problems for AD studies. The goal is to create and test an independent population that is large enough to provide statistical power needed to avoid high false-negative and false-positive errors (26, 27) . Substantial barriers exist to using microarrays in clinical applications, especially the need for developing platforms that will yield significant and reproducible results (28) . Efforts by Shi et al (25) are providing useful insights into the analysis of the problems inherent to comparing results across platforms, and ongoing studies are trying to determine what significantly contributes to noise inherent to a platform, for example, choice of probe length, locus of probe used to detect the gene, the number of probes per gene and, how the probe signals are averaged. Despite these shortcomings, microarray studies have successfully generated substantial findings regarding gene expression during different neuropathic conditions.
How Microarrays Have Dissected Molecular Mechanisms of Disease Biomarker Discovery
Examination of tissue gene expression signatures can be used to provide diagnostic information complementary to existing pathology and clinical chemistry techniques. Although these technologies are widespread in research environments, necessary regulations are still being developed for these new technologies in clinical applications. At present, a few types of complex microarray tests are becoming available through high complexity Clinical Laboratory Improvement Amendments (CLIA) -certified diagnostic laboratories. It is expected that these services will proliferate and develop in those facilities that can meet the CLIA microarray manufacturing requirements and that regulatory approval by the FDA will follow for widespread clinical applications. Gene expression patterns have been shown to be specific for particular disease types and stages. In simple and clearcut cases, these are gene sets that distinguish tumors of different origins. In more complicated and more interesting cases, these gene sets can be used as indicators for patient prognosis; for example, 5-year survival for breast cancer (29) and prognosis of fibrosis development for hepatitis C virus-infected patients (30) .
It is theorized that meaningful changes in patterns of expression of multiple genes or the presence of deleterious nucleic acid sequences (e.g. viral DNA or single nucleotide polymorphisms that predispose to disease) are prerequisites of disease development and that they accumulate before any observable symptoms. Observations in a variety of studies suggest that multiplex measurements, although more complicated to analyze, may ultimately be more accurate than existing criteria for diagnoses based on a few clinical or biologic measurements. For example, the study by Weigelt et al (29) shows that their set of gene markers is a more accurate predictor of breast cancer mortality than a set of National Institutes of Health-defined clinical guidelines. Microarrays have been used in multiple studies to detect changes in the mRNA profile in the hippocampus of patients with AD, and these results were confirmed by immunohistochemical labeling of the translated proteins (31).
Genetic Markers of Disease and/or Disease Progression
Microarrays have use both in the discovery and clinical validation phases of diagnostics development. However, for technical, regulatory, or fiscal reasons, microarrays are often used as tools to identify single or multiple biomarkers that are then screened for using more established techniques such as quantitative PCR immunoassays. A good example of the targets of these studies is single genes that are differentially expressed at certain disease stages, like those that encode soluble secreted proteins that could be found in the patient's blood (or cerebrospinal fluid). These genes can be identified at the mRNA level and then tested by identifying corresponding proteins. Many signaling components such as chemokines and cytokines are good examples of more accessible diagnostic biomarkers identified by microarray screens (30, 32, 33) .
Alternatively, microarrays themselves have been applied directly to tissues that are distal to the diseased tissue. A common example is the application of microarrays for profiling the gene expression of peripheral blood lymphocytes during the analysis of gene expression changes associated with the antidepressive drug, venlafaxine, used to treat mood disorders (34) , psychologic stress responses (35) , and AD (36) . This pilot study of gene expression profiles of peripheral blood cells in 16 patients with AD and aged control probands showed that 20 genes were associated with AD lymphocytes as compared with control lymphocytes. Among these genes were the >2C-adrenoreceptor gene, known to regulate blood pressure and learning; defensin, a histocompatability complex enhancer-binding protein; carboxypeptidase M; and the Fc fragment of IgE known to be involved in cellular and humoral immune responses. Others associated with AD, like the human cell death protein, TRAIL, and galectin-4, were factors shown to participate in the regulation of apoptosis. It was suggested that the altered expression profile of these genes might be connected with the previously reported AD-specific lymphocyte abnormalities.
statistical significance and an extensive knowledge of the possible relevant genes because the genome is too large to randomly search for single nucleotide changes that may or may not be relevant to a disease state. However, in contrast to expression analysis based on mRNA, samples for genotyping are much easier to obtain because any tissue in the patient can be sampled for the genomic DNA, and samples tend to be much less effected by the time ex vivo or postmortem occurs. An example of genomic studies in AD has been performed by Emilsson et al (37) , who demonstrated that a rare haplotype (ATAG) regulator of G-protein signaling 4 (RGS4) is associated with decreased mRNA levels in both cases and controls.
Drug Development

Characterization of Pathways and Mechanisms of Disease Onset and Progression
Postmortem biopsies could be very relevant in analyzing mechanisms, especially if some early-stage samples are available (from patients who die from nondisease-related ailments). Knowledge of mechanisms can identify potential targets that may respond to drugs in addition to sets of genes for multiplex nucleic acid diagnostics. However, the big challenge from a drug development perspective is correlating altered expression observed by a microarray with susceptibility to drugs because mRNA expression is not always a good indicator of the functional significance of a protein's activity in a disease state. In addition, although many promising studies of AD have been carried out with microarrays, which demonstrate the presence of genes that may be potential targets for therapy (38) , the sample sizes are often small. Therefore, a great deal of additional work is required to ensure that the observed changes are reproducible over clinically relevant populations.
Microarray-based studies of gene expression in Parkinson disease have identified that 570 genes were found to be differentially regulated in neuropathologically confirmed cases of sporadic Parkinson disease, particularly the DNAJ chaperones (39). Xiang et al (40) used similar tools to study pathologic mechanisms of sporadic Creutzfeldt-Jakob disease (sCJD) in the central nervous system. Here, the major alterations in sCJD brains included upregulation of the genes encoding immune factors, stressYresponse factors, and elements involved in cell death and the cell cycle as well as prominent downregulation of genes encoding synaptic proteins. Conspicuously, sCJD brains showed great similarity with aging human brains both in the global expression patterns and in the identified differentially expressed genes. In another study, gene expression changes in hippocampal dentate granule neurons revealed possible mechanisms for schizophrenia. Compared with 24 control cases, the 22 patients with schizophrenia revealed decreases in clusters of genes that encode for protein turnover (proteasome subunits and ubiquitin), mitochondrial oxidative energy metabolism, and genes associated with neurite outgrowth, cytoskeletal proteins, and synapse plasticity. These changes were not obtained in 9 bipolar cases or 10 major depression cases and were not associated with age, sex, brain weight, body weight, postmortem interval, or drug history. Thus, a mitochondrial and ubiquitinYproteasome hypofunctioning of dentate granule neurons may contribute to the deficits of schizophrenia (41) .
An elegant study by Lu et al (42) has revealed some mechanisms of aging in the human brain. Transcriptional profiling of the human frontal cortex from individuals ranging from 26 to 106 years of age defines a set of genes with reduced expression after age 40. These genes play central roles in synaptic plasticity, vesicular transport, and mitochondrial function. This is followed by induction of stress response, antioxidant, and DNA repair genes. DNA damage is markedly increased in the promoters of genes with reduced expression in the aged cortex. Moreover, these gene promoters are selectively damaged by oxidative stress in cultured human neurons and show reduced base excision DNA repair. Thus, DNA damage may reduce the expression of selectively vulnerable genes involved in learning, memory, and neuronal survival, initiating a program of brain aging that starts early in adult life.
Studies of human postmortem brain-derived microglia from patients with AD (43) show clear inflammatory responses when analyzed by microarray techniques. Additionally, Blalock et al (44) performed a global gene analysis of AD in human postmortem brain using the hippocampal gene expression of 9 control and 22 AD subjects of varying severity on 31 separate microarrays. Correlation of the data from microarrays with Mini-Mental Status Examination (MMSE) and NFT scores was made across all 31 subjects regardless of diagnosis. A major transcriptional response involving thousands of genes significantly correlated with AD markers. Biologic process categories associated with incipient AD-correlated genes were identified, and they revealed upregulation of many transcription factor/signaling genes regulating proliferation and differentiation, including tumor suppressors, oligodendrocyte growth factors, and protein kinase A modulators. In addition, upregulation of adhesion, apoptosis, lipid metabolism, and initial inflammation processes occurred, and downregulation of protein folding/metabolism/transport and some energy metabolism and signaling pathways took place.
Validation of Experimental Models of Diseases
Cell Cultures
Microarray analysis has been applied to determine how relevant an in vitro model is to the actual disease state. Bachoo et al (45) studied in vitro model systems of astrocyte differentiation, primary astrocyte cultures, and various astrocyte-rich central nervous system structures using microarray technology to gain perspective on how astrocytes may participate in the pathogenesis of common neurologic disorders like AD, Parkinson disease, stroke, epilepsy, and primary brain tumors.
Comparative Biology
A related approach can be applied to test how similar an in vivo model may be to the observed human disease state because microarrays provide a reasonably comprehensive picture of global gene expression. However, it is likely that homologous genes have somewhat different roles between organisms, so the interpretation can (again) be complex. Studies of various neurodegenerative models such as induced pathologies in the nematode Caenorhabditis elegans, the fruit fly Drosophila melanogaster, and the mouse Mus musculus have attempted to imitate the pathology process of AD to better understand cellular mechanisms and possible therapeutic interventions. Among many in vitro and in vivo models of AD, transgenic C. elegans expressing human AA has shown some changes reminiscent of the disease state in humans: DNA microarray assays of the worm demonstrated several upregulated stress-related genes, particularly 2 genes homologous to human >B-crystallin and tumor necrosis factor-related protein. Both have also been observed to be upregulated in postmortem AD brain (46) .
Three mouse models of AD were used to assess changes in gene expression potentially critical to AApeptide-induced neuronal dysfunction (46) . Thirty-four gene changes were identified among the 3 models in mice with AA deposition. Among the upregulated genes, 3 major classes identified encoded for proteins involved in immune responses, carbohydrate metabolism, and proteolysis. Downregulated genes of note included pituitary adenylate cyclaseactivating peptide, brain-derived neurotrophic factor, and insulin-like growth factor I receptor. Finally, changes in gene expression among the three mouse models of AD were compared with those reported in human AD samples. Sixtynine upregulated and 147 downregulated genes were found in common with human AD brain. These comparisons across different genetic mouse models of AD and human AD brain provide greater support for the involvement of identified gene expression changes in the neuronal dysfunction and cognitive deficits accompanying amyloid deposition.
Progress Toward the Clinical Application of Microarrays
Microarray technology has great potential to allow for increased understanding of gene expression and phenotype. Clearly, there is potential for this technology to be applied to diagnostics, and in the United States, the FDA has announced it will be setting clear guidelines for the application of microarray technology to human molecular diagnostics by 2008. In the meantime, the FDA has reviewed and is reviewing a number of commercial platforms based on microarray or highly parallel nucleic acid analysis technology. Despite issues with increased test complexity, which are partly responsible for the slower deployment of such technologies, there is clearly benefit to microarraybased systems for disease diagnosis. At present, microarray technologies are clearly in the realm of highly complex tests, but the potential of the technology to discriminate and stratify subpopulations of patients to widen the therapeutic window is tantalizing.
Current molecular diagnostic tests monitor single or small groups of markers. These are generally antibody-based serum tests, simple to run, and straightforward to apply in a clinical reference laboratory. Numerous studies have demonstrated the use of microarray analysis of large cohorts of biomarkers for disease classification. However, sample handling issues, data quality, and the risks with misinterpreting large multivariate data sets means that this powerful technology requires significant specialized knowledge to apply in a diagnostic setting. On the other hand, in scenarios in which conclusive diagnosis is difficult or impossible with existing tools available to the clinician, these advanced technologies become very important. Indeed, it is in these areas of medicine that advanced technologies such as microarrays are most likely to be applied more aggressively to seek a definitive diagnosis. The most well-known examples of pioneering applications of multiplex analysis of gene expression are in tumor biology, where specific grades of tumors or similar types of lymphomas are difficult to resolve by classic histopathology. In these cases, tumor biopsy samples are analyzed to determine the gene expression pattern specific to that tumor, creating distinct tumor subclasses that associate with different therapeutic approaches (47, 48) . The obstacle in the diagnosis of neurodegenerative disease is that antemortem biopsy tissue is hard to come by, and therefore the same approach used for cancer gene expression profiling is not practical to apply. However, the search for biomarkers outside the brain of the demented patient is crucial, and advanced forms of nucleic acid analysis remain critical research tools. In general, this technology has the greatest potential for diagnostics in which histologic differentiation is difficult or not feasible.
Early clinical molecular detection for AD is currently nonexistent, and diagnosis and treatment are only initiated once a mild to moderate disease state has been assessed through cognitive decline. Molecular detection strategies are in the early stages of development and have focused on factors previous known to participate in initiation and progression (49) . These studies have focused on cerebrospinal fluid, which has the advantage of being in close contact with the disease site, but it is still not practical for routine screening. The simplest solution would be to monitor gene expression signatures in the peripheral blood because blood easily obtained on a routine basis, and the time ex vivo could be controlled by using blood is collection techniques that stabilize the RNA. Promising studies have indicated that peripheral blood lymphocytes can be used as an appropriate proxy. Microarray studies between patients with AD and control subjects in populations of lymphocytes demonstrate sensitivity to a wide range of stimuli, including markers that seem to be disease-specific (50) . These studies showed that gene expression patterns were also modulated in response to the antidepressant drug mirtazapine in both control and AD subjects. Furthermore, there were specific proteins differentially expressed in patients with AD that were not observed in control subjects (50) . These proteins had previously been observed to be differentially expressed in the AD brain or correlated with the disease. Related studies have indicated that AD lymphocytes respond differently to antidepressant treatment and that decreased expression of cytoskeletal proteins in the lymphocytes might correlate with AD pathology (51) . The degree to which disease in the hippocampus can be reliably detected through monitoring of gene expression analysis of white blood cells in large clinical cohorts remains to be seen. Because peripheral blood lymphocyte populations undergo very significant biologic changes in the active immune system and are clearly affected by certain drug therapies and the aging process itself, it is likely that the accurate molecular diagnosis of AD through peripheral blood gene expression will be difficult to implement. However, with future improvements in these methods, it may become possible to track treatment progress with microarrays, serving as an adjunct to conventional MMSE monitoring methods.
The Future of Microarray Technology
Newer microarray systems are providing additional tools as systems become easier to customize for specific applications and effective data analysis tools become more mainstream. Although, in theory, it has always been possible to customize any microarray, it has either been impractical, too costly, or too labor-intensive to make changes to microarray designs. The significance of this feature is that a variety of new applications are being developed for microarrays, some of which are beneficial to the study of AD. In addition to standard Bboilerplate[ human genome microarrays, new designs are appearing that can more easily interrogate splice variants, small RNA species (microRNAs [52] ), polymorphic regions, and a whole host of transcriptionally active areas of the genome that have previously been ignored. In addition, techniques have been developed to analyze methylation patterns, known to alter during aging, using microarrays on a genomewide scale. Microarrays are now widely applied to chromosomal aberration analysis rather than using fluorescence in situ hybridization, and they are used as a tool to identify novel pathogens associated with disease (e.g. the DeRisi Bvirochip[). A whole host of proteinYDNA hybrid assays are also being developed to analyze the transcriptional activity of promoters or repressors across large segments of the genome. This technique is called on chip chromatin immunoprecipitation, or ChIP on chip. In addition to studying nucleic acids, arrays are also being used to analyze protein expression, although given the experience with nucleic acid microarrays, truly large-scale proteomic arrays are also going to prove to be complex and technically challenging.
Array formats are varying as well, and the assay user is able to choose from a wide variety of densities ranging from a few thousand features to well over one million (Illumina, Affymetrix). Although bigger is sometimes better, the medium-and low-density formats are generally better for focused studies and do not incur the large data analysis and data storage burden implicit with super-high-density arrays.
The cost to use microarrays is also decreasing rapidly. This fact is important because early microarray studies experienced lack of technical and biologic replicates as a result of the high costs of purchasing arrays. Newer systems are cheaper to acquire and, similar to the more classic nylon hybridization membrane technology, can even be reused multiple times with good results. This is in stark contrast to classic glass slide microarrays, which degrade rapidly during the stripping step after hybridization as the surface chemistry linking the DNA probe to the substrate is perturbed.
Obviously, reuse of a microarray is not suitable for every application; however, there are circumstances when chip reuse can be highly beneficial to controlling costs when running large microarray studies.
The most probable changes in the microarray arena are likely to be associated with reducing the cost and complexities of the microarray systems. These are clearly barriers to the widespread adoption of these technologies outside of the research laboratory environment. In addition, the large emphasis of microarray manufacturers and working groups on microarray standardization and benchmarking will help to dispel a great deal of the myths and misinformation surrounding these tools, enabling a smooth transition for these technologies into the diagnostic market space.
